Overview

A Study of Mitoxantrone Hydrochloride Liposome Injection in Subjects With Advanced Bone and Soft Tissue Sarcoma

Status:
Not yet recruiting

Trial end date:
2023-06-01

Target enrollment:

Participant gender:

Summary

This is a multicenter, open-label, phase Ib study to evaluate the safety and efficacy of Mitoxantrone Hydrochloride Liposome in subjects with unresectable or metastatic bone and soft tissue sarcoma who has failed at least one prior line of therapy.

Phase:

Phase 1

Details

Lead Sponsor:

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Treatments:

Mitoxantrone